Literature DB >> 28766129

Use and safety of antiepileptic drugs in psychiatric inpatients-data from the AMSP study.

Katrin Druschky1, Stefan Bleich2, Renate Grohmann3, Rolf R Engel3, Alexandra Kleimann2, Susanne Stübner3, Waldemar Greil3,4, Sermin Toto2.   

Abstract

The psychiatric utilization patterns and risks of antiepileptic drugs (AEDs) were assessed by using data from the drug safety programme Arzneimittelsicherheit in der Psychiatrie over the time period 1993-2013. In a total of 432,215 patients, the main indications for AED use were acute mania, schizoaffective disorder, and schizophrenic and organic psychoses. Valproic acid (VPA) was the most common substance across all of those groups, reaching administration rates of up to 50% since 2005, at which time carbamazepine (CBZ) administration consistently dropped below a rate of 10%. Lamotrigine (LTG) and pregabalin (PGB) increased in relevance after 2005 and 2010, respectively (with administration rates of up to 9%), whereas oxcarbazepine (OXC) was least prevalent (<3%). The mean rates of severe adverse drug reactions (ADRs) ranged from 6 cases per 1000 patients treated (VPA) to 19/1000 (OXC) and were significantly lower with treatment with VPA compared to OXC and CBZ. Hyponatremia was the leading ADR during treatment with OXC; severe allergic skin reactions were most often observed during treatment with CBZ and LTG, and severe oedema was most common during treatment with PGB. Severe hyponatremia induced by OXC was observed significantly more often in female patients than in male patients.

Entities:  

Keywords:  AMSP programme; Adverse drug reactions; Antiepileptic drugs; Drug utilization

Mesh:

Substances:

Year:  2017        PMID: 28766129     DOI: 10.1007/s00406-017-0827-5

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  88 in total

1.  [Dipropylacetamide in the treatment of manic-depressive psychosis].

Authors:  P A Lambert; G Carraz; S Borselli; M Bouchardy
Journal:  Encephale       Date:  1975       Impact factor: 1.291

2.  Efficacy and Safety of Pregabalin in Patients with Fibromyalgia and Comorbid Depression Taking Concurrent Antidepressant Medication: A Randomized, Placebo-controlled Study.

Authors:  Lesley M Arnold; Piercarlo Sarzi-Puttini; Pierre Arsenault; Tahira Khan; Pritha Bhadra Brown; Andrew Clair; Joseph M Scavone; Joseph Driscoll; Jaren Landen; Lynne Pauer
Journal:  J Rheumatol       Date:  2015-06-01       Impact factor: 4.666

3.  Buprenorphine and carbamazepine as a treatment for detoxification of opiate addicts with multiple drug misuse: a pilot study.

Authors:  U Schneider; W Paetzold; V Eronat; T J Huber; J Seifert; B Wiese; H M Emrich
Journal:  Addict Biol       Date:  2000-01-01       Impact factor: 4.280

4.  Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder.

Authors:  O C Pinto; H S Akiskal
Journal:  J Affect Disord       Date:  1998-12       Impact factor: 4.839

Review 5.  Report of the WPA section of pharmacopsychiatry on the relationship of antiepileptic drugs with suicidality in epilepsy.

Authors:  Konstantinos N Fountoulakis; Xenia Gonda; Thomas C Baghai; David S Baldwin; Michael Bauer; Pierre Blier; Wagner Gattaz; Gregor Hasler; Hans-Jürgen Möller; Rajiv Tandon; Eduard Vieta; Siegfried Kasper
Journal:  Int J Psychiatry Clin Pract       Date:  2015-04-23       Impact factor: 1.812

6.  Oxcarbazepine: preclinical anticonvulsant profile and putative mechanisms of action.

Authors:  M Schmutz; F Brugger; C Gentsch; M J McLean; H R Olpe
Journal:  Epilepsia       Date:  1994       Impact factor: 5.864

Review 7.  [Value of old and new anticonvulsants in treatment of psychiatric diseases].

Authors:  J Walden; B Hesslinger
Journal:  Fortschr Neurol Psychiatr       Date:  1995-08       Impact factor: 0.752

8.  A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia.

Authors:  Lesley M Arnold; I Jon Russell; E W Diri; W Rachel Duan; James P Young; Uma Sharma; Susan A Martin; Jeannette A Barrett; George Haig
Journal:  J Pain       Date:  2008-06-03       Impact factor: 5.820

9.  Hyponatremia induced by oxcarbazepine.

Authors:  A C Johannessen; O A Nielsen
Journal:  Epilepsy Res       Date:  1987-03       Impact factor: 3.045

Review 10.  Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention.

Authors:  Borwin Bandelow; Dirk Wedekind; Teresa Leon
Journal:  Expert Rev Neurother       Date:  2007-07       Impact factor: 4.618

View more
  6 in total

1.  Osteogenic Effect of Pregabalin in Human Primary Mesenchymal Stem Cells, Osteoblasts, and Osteosarcoma Cells.

Authors:  Nele Wagener; Pietro Di Fazio; Kai Oliver Böker; Georg Matziolis
Journal:  Life (Basel)       Date:  2022-03-28

2.  Sex Differences in the Risk of Cutaneous Adverse Drug Reactions Induced by Antiseizure Medications: A Systematic Review and Meta-analysis.

Authors:  Israa Alfares; Muhammad Shahid Javaid; Zhibin Chen; Alison Anderson; Ana Antonic-Baker; Patrick Kwan
Journal:  CNS Drugs       Date:  2021-02-12       Impact factor: 5.749

3.  Acute hyponatremia with accompanying hyperammonemia secondary to divalproex sodium: A case report.

Authors:  Ashley J Maister; Gregory T Bogart
Journal:  Ment Health Clin       Date:  2018-06-29

4.  Serum Sodium Concentration and Increased Risk for Primary Epiretinal Membrane.

Authors:  Can Can Xue; Jing Cui; Xiao Bo Zhu; Jie Xu; Chun Zhang; Dong Ning Chen; Ya Xing Wang; Jost B Jonas
Journal:  Front Med (Lausanne)       Date:  2021-12-24

5.  Hemodiafiltration Treatment for Severe Valproic Acid Intoxication: Case Report and Updated Systematic Literature Review.

Authors:  Tobias Tichelbäcker; Judith Herath; Björn Tampe; Peter Korsten
Journal:  Front Med (Lausanne)       Date:  2018-08-10

6.  Psychotropic drug-induced hyponatremia: results from a drug surveillance program-an update.

Authors:  Johanna Seifert; Martin Letmaier; Timo Greiner; Michael Schneider; Maximilian Deest; Christian K Eberlein; Stefan Bleich; Renate Grohmann; Sermin Toto
Journal:  J Neural Transm (Vienna)       Date:  2021-07-01       Impact factor: 3.575

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.